1	Adverse events following immunization during COVID-19 mass
2	vaccination campaigns in the Democratic Republic of Congo:
3	Findings from active safety surveillance
4	Kizito Kayumba ^{1*} , Alemayehu Duga ¹ , Mosoka Papa Fallah ¹ , Claire Tshidibi ² , Nicky Lubaki ² ,
5	Barnabas Coulibaly ¹ , Benjamin Djoudalbaye ¹ , Efire Nora Sylvana ¹ , Elizabeth Gonese ¹ , Senga
6	Lucy Sembuche ¹ , Tedi Tilahun ¹ , Murtala Jibril ¹ , Carlos Kilowe ¹ , Aminu Kuba ¹ , Antoine Mafwila
7	Lusala ¹ , Nebiyu Dereje ¹ , Nicaise Ndembi ¹ , Tajudeen Raji ¹ , Ngashi Ngongo ¹
8	
9	Affiliations
10	¹ Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia
11	² Ministry of Health, Kinshasa, Democratic Republic of Congo
12	
13	* Corresponding author
14	E-mail: KizitoK@africacdc.org (KK)
15	
16	Contributorship
17	"KK and AD are Joint First Authors"
18	

19

20

21 Abstract

Introduction: Post-marketing safety surveillance is indispensable for ensuring safety and public trust in vaccines, particularly in African settings where evidence of COVID–19 vaccine safety is less documented. We aimed to identify the types of adverse events following immunization (AEFIs), the overall incidence, and factors associated with AEFIs during mass vaccination campaigns in The Democratic Republic of Congo (DRC).

27 **Methods**: From December 1 to 29, 2023, a prospective safety surveillance study was conducted 28 on 4,766 individuals in Kinshasa Province in DRC. They were surveyed through phone calls from 29 day 1 to 28 following the administration of the COVID-19 vaccine. We calculated AEFI incidence 30 rates by type of vaccine, sex, and age group. We identified factors associated with AEFIs using 31 multivariable logistic regression models, which were expressed by adjusted odds ratio (aOR) and 32 its 95% confidence interval (CI).

33 Results: A total of 4766 participants were included in the study. The median age of the participants was 36 years, with an interguartile range of 27 to 48 years and 2503 (53%) were 34 35 females. Most of the participants (94.6%) received the Johnson & Johnson (J&J) vaccine, while 256 (5.4%) received the Pfizer vaccine. Nearly a quarter of participants (23.75%, 95% CI: 22.54%-36 24.99%) reported AEFIs. The most common AEFIs reported were fever (9.61%, 95%CI: 8.88%-37 10.48%), injection site pain (9.00%, 95%CI: 8.20%-9.85%), headache (4.11%, 95%CI: 3.57%-38 4.72%), stiffness (1.51%, 95%CI: 1.18%-1.89 %) and myalgia (1.15%, 95%CI: 0.87%-1.49%). The 39 40 incidence of AEFIs was higher for the Pfizer vaccine at 34.48% (95% CI: 28.57%-40.54%) compared

41	to 23.15% (95% CI: 21.92%-24.41%) for the J&J vaccine. Participants aged 36 years and above
42	were associated with increased odds of reporting any adverse event (aOR=1.17, 95%CI: 1.02-
43	1.33), injection site pain (aOR=1.36, 95% CI: 1.11-1.66), and two or more signs (aOR=1.46, 95%CI:
44	1.10-1.94), compared to those below 36 years of age.
45	Conclusions: AEFI reported by about a quarter of participants and its association with vaccine
46	type and older age underscores the need for systematic vaccine safety monitoring in the
47	population. This is critical for developing future vaccination strategies tailored to individuals
48	more susceptible to AEFIs.
49	Keywords: COVID-19 vaccines, Safety surveillance, Pharmacovigilance, Adverse Event
50	Following Immunization, The Democratic Republic of Congo, Africa CDC, Mass Vaccination
51	Campaign.

52

53

54 Introduction

Vaccines approved for use in national immunization programmes (NIPs) are considered safe and efficacious based on verifiable evidence from randomized controlled clinical trials (RCTs)¹. These trials provide robust evidence supporting their safety and effectiveness. However, despite the rigorous evaluation during clinical development, it is important to note that rare side effects may not be detected in the early phases of clinical trials. Post-marketing safety surveillance after introducing the COVID-19 vaccine into public immunization programs must identify rare and

previously undocumented adverse events (AEs) to address this. For instance, the non-replicating vector COVID-19 vaccines such as AstraZeneca and Johnson & Johnson have been associated with central venous sinus and other large vessel thrombosis (~4 per million vaccinations) and thrombocytopenia. ² Similarly, messenger RNA COVID-19 vaccines have also observed rare side effects, such as Pfizer-BioNTech. These include anaphylaxis and myocarditis.³ Moreover, the African population was not adequately represented in RTCs. Therefore, the safety of the vaccines can only be determined by post-market safety surveillance.

Given that vaccines are often recommended for healthy individuals, the key to the success of 68 NIPs is public trust in vaccine safety. ⁴ Thus, systematic vaccine safety surveillance is 69 70 indispensable for ensuring the safety and public trust in vaccines. Safety surveillance is expected to provide additional information on incidence, distribution, and risk factors for expected and 71 unexpected serious and minor AEFIs.⁵ According to the World Health Organization (WHO), all 72 73 adverse events(AEs) that concern the caregiver and have associated costs and effects should be reported regardless of severity.⁶ The present study aimed to investigate the occurrence of AEFI 74 during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo. By 75 76 conducting a thorough analysis of AEFI data collected from these campaigns, this study sought to provide valuable insights into the safety profile of vaccines administered. It contributed to the 77 evidence base for future vaccination efforts. 78

79

80

82 Methods

83 Study Setting and Design

We conducted a prospective follow-up study using an active safety surveillance approach among 84 COVID-19 vaccine recipients in the Democratic Republic of Congo (DRC). As of June 2023, 17.05 85 86 million individuals in the DRC have received at least one dose of COVID-19 vaccine.⁷ The Ministry 87 of Public Health of the DRC, through the Expanded Programme on Immunization (EPI), with the support of Africa Centres for Disease Control and Prevention (Africa CDC) and implementing 88 partners, conducted a two-week Rapid Results Initiative (RRI) COVID-19 mass vaccination 89 campaign. From December 1 to 29, 2023 in Kinshasa province, selected vaccine recipients were 90 91 recruited for the follow-up. The campaign's primary objective was to accelerate the COVID-19 vaccination efforts and improve the low vaccination coverage in DRC. Africa CDC and EPI 92 conducted COVID-19 vaccine safety surveillance to document AEFI during the campaign. 93

During this mass vaccination campaign in the DRC, two types of COVID-19 vaccines were administered: the Pfizer-BioNTech mRNA vaccine and the Johnson & Johnson (J&J) nonreplicating vector vaccine. The Pfizer-BioNTech vaccine utilizes mRNA technology to train the immune system to recognize the spike protein of the coronavirus.⁸On the other hand, the J&J vaccine delivers the virus' DNA to host cells using an adenovirus as a delivery vehicle).⁹

99 Study participants

100 The COVID-19 mass vaccination campaign occurred in 159 vaccination sites distributed in 29 101 health zones of Kinshasa Province. In each vaccination site, 5% of the people vaccinated were

randomly selected for safety surveillance, according to the WHO recommendation⁵. Those
 participants who received COVID-19 vaccines during the campaign consented to participate in
 the study and provided a reachable phone number.

105 Data Collection and Management

We used a structured guestionnaire adapted from the WHO safety surveillance tool⁵. The tool 106 107 captured data on population characteristics such as patient ID, province, profession, sex, and age, as well as vaccine-related information such as batch number, number of doses, type of vaccine, 108 vaccination date, and the record of AEF. The data concerning AEFI included the date of the caller, 109 110 the date of onset of the event and the type of AEFI. Follow-up calls were made on days 1, 3, 5, 7, 14, 21, and 28 after vaccine administration and data collection forms were used to record 111 112 information. The AEFI was considered serious in case of an event that results in death, 113 hospitalization, or prolongation of an existing hospitalization, persistent or significant disability 114 or incapacity, congenital anomaly/birth defect, or is life-threatening or is a medically important event or reaction.⁵ Africa CDC recruited and trained a local team of AEFI focal points to conduct 115 follow-up calls to identify and monitor the AEFI. A data collection line listing form with built-in 116 validation rules was used to ensure data quality during data entry. 117

118

Data Analysis

120 The study's primary outcome was the experience of at least one AEFI among those receiving at 121 least one dose of any COVID-19 vaccine used during the vaccination mass campaign. Eight

Adverse Events for Special Interest (AESI) conditions pre-defined for surveillance based on WHO recommendation, including fever, vomiting, headache, muscle pain, joint pain, body aches, persistent pain at the injection site, diarrhea, and chills, were followed and monitored. We dichotomized the number of events as 2 or more coded as one (1) and 0–1 coded as zero (0) for our logistic regression model for the number of AEs ¹⁴. The independent variables considered in this analysis included age (dichotomized as <36 years and \geq 36 years), sex, type of COVID-19 vaccines, and the number of COVID-19 vaccine doses received.

129 Descriptive statistics were used to summarize socio-demographic characteristics and vaccine-130 related information by frequency and proportion for categorical variables and median with interguartile range (IQR) for numerical variables. The cumulative incidence rate of AEFI was 131 132 provided by proportion along with its respective 95% confidence interval. The multivariate regression models for statistical analysis using the backward-elimination regression approach 133 134 included all the above-mentioned independent variables. Multicollinearity was assessed by the 135 variance inflation factor (VIF) and the tolerance test (≥0.1). The VIF below ten was considered acceptable to declare lack or absence of multicollinearity. Variables with collinearity were 136 omitted from the models. The goodness of model was assessed by the Hosmer Lemeshow 137 goodness of fit test (P-value >0.05). Multivariable logistic regression models identified factors 138 139 associated with experiencing AEFI and expressed by adjusted odds ratio (aOR) and its 95% CI. A 140 p-value < 0.05, together with 95%CI, was used to declare statistical significance. Stata IC version 16 (Stata Corp) was used to analyze the data in this study. 141

143 Ethical considerations

144	After the vaccine was administered, selected participants were informed about the purpose of
145	this surveillance and were asked to willingly participate in this survey. The consent was obtained
146	verbally. The verbal consent was documented on vaccine recipients' follow up form and
147	witnessed by the enumerator. Those who consented provided their phone numbers to enable
148	follow-up calls. The parents' phone numbers were provided for the vaccine recipients under 18.
149	To ensure confidentiality, de-identified data was shared with Africa CDC to analyze the vaccine's
150	safety profile following immunization. Ethical Approval was obtained from the appropriate
151	Institutional Review Board to conduct this survey and publish the findings from this analysis.

152 **Results**

153 Population and Vaccine Characteristics

- The analysis included 4766 participants, with a median age of 36 (Interquartile Range [IQR]: 2748). More than half (53%) of the participants were females, and more than 70% of respondents
 were in the 20—to 49-year age range.
- 157 Most participants (94.4%) received the Johnson & Johnson vaccine, and the remaining 5.6% were 158 vaccinated with the Pfizer vaccine. Those taking their second dose were 0.6%, and 99.4% took 159 their first dose (Table 1).

160

162 **Table 1: Population and vaccine characteristics**

Variables (N= 4766)	Group	N	% (95%CI)
Sex	Male	2,263	47.48 % (46.06%-48.91%)
	Female	2,503	52.51% (51.09-53.94%)
Type of Vaccine	181	4,509	94.61% (93.93%-95.23%)
	Pfizer	256	5. 37% (4.75%-6.05%)
Number of doses	First	4,739	99.43% (99.18%-99.63%)
	Second	27	0.57% (0.37%-0.82%)
	<12 years	2	0.04% (0.01-0.15%)
	12-17 years	38	0.78% (0.56%-1.09%)
	18-19 years	171	3.58% (3.08%-4.16%)
Age Groups	20-29 years	1,343	28.18% (26.90%-29.47%)
0	30-39 years	1,236	25.93% (24.69%-27.20%)
	40-49 years	882	18.51% (17.41%-19.63%)
	50-59 years	626	13.13% (12.19%-14.12%)
	60+ years	467	9.79% (8.97%-10.68%)
Seriousness of AEFIs	Serious	6	0.13% (0.05%-0.27%)
	Non-serious	4760	99.87% (97.73%-99.95%)

163

165 Incidence and Forms of AEFI Reported

- 166 Overall, 1131 (23.75%, 95% CI: 22.55% 24.99%) reported having developed at least one AEFI
- 167 during the study period. The most frequent forms of AEFI reported (ranging between 1% to 10%)
- are fever 458(9.61%, 95%CI: 8.88%-10.48%) followed by pain on injection site 429 (9.00%, 95%CI:
- 169 8.20%-9.85%), headache 196 (4.11%, 95%CI: 3.57%-4.72%), stiffness 72 (1.51%, 95%CI: 1,18%-
- 170 1.89%) and myalgia 55(1.15%, 95%CI: 0.87%-1.49%). The less frequent forms (ranging between
- 171 0.1% to 1%) include vomiting 24 (0.50%, 95%CI: 0.32%-0.75%), arthralgia 18(0.38%, 95%CI:
- 172 0.22%-0.59%), diarrhea 12(0.25%, 0.13%-0.44%), vertigo 12(0.25%.95%CI: 0.13%-0.44%) and
- 173 chills 10 (0.21%, 95%CI: 0.10%-0.38%). The unusual AEFIs reported (ranging between 0.01% to
- 174 0.1%) are heaviness of arm 4 (0.08%, 95%CI: 0.02%-0.21%), gastritis 2 (0.04%, 95%CI: 0.010%-
- 175 15%), blood pressure 1(0.02%, 95%CI: 0.01%-0.11%)), blurred vision 1 (0.02%, 95%CI: 0.01%-
- 176 0.11%), burning sensation 1 (0.02%, 95%CI: 0.01%-0.11%) (Figure 1)

177 Figure 1: Frequency of reported AEFIs

178 Factors Associated with the Incidence of AEFIs

In the multivariable analysis, the occurrence of an AEFI was statistically associated with age and the type of vaccine administered. Incidence of AEFI was higher among Pfizer vaccine recipients (34.38%, 95% CI: 28.57%%-40.54%) versus J&J vaccine recipients (23.15%, 95% CI: 21.92%-24.41%); slightly higher among vaccine recipients aged 36 years and more (25.11%, 95%CI: 23.39%-26.88%) versus those below 36 years of age (22.34%, 95% CI: 20.66%-24.08%). The odds of any AEs were about two times higher in the Pfizer vaccine (aOR, 1.73; 95% CI: 1.31-2.28); p<0.001) as compared to J & J vaccine recipients and 17% higher among the older age group

- 186 (aOR, 1.17, 95%CI: 1.02-1.33; p<0.022) at 36 years and more vs. <36 years. No statistical
- association was found for gender and number of doses (Table 2).

188 Table 2: Factors associated with the incidence of AEFIs

Independent	Group	AEFI	AEFI	% AEFI	aOR (95%CI)	P-value
Variables		(-)	(+)			
	Male	1,908	595	23.77%	1.00 (0.87-1,14)	0.986
Gender	Female	1,726	537	23.70%	1 (Ref)	
	36 Years and +	1,819	610	25.11%	1.17 (1.02-1.34)	0.022*
Age	<36 years	1,815	522	22.34%	1 (Ref)	
	Pfizer	168	88	34.38%	1.73 (1.32-2.28)	0.001*
Type of Vaccine	Johnson &	3,466	1,044	23.15%	1 (Ref)	
	Johnson					
Number of doses	1 st dose	3,613	1,126	23.76%	1.87(0.73-4.79)	0.190
administered	2 nd dose	21	6	22.22%	1 (Ref)	

189 * Significant factors, p<0.05

Fever was higher for Pfizer vaccine recipients (12.50%, 95%CI; 8.71%-17.18%) than J&J vaccine
recipients (9.45%, 95%CI: 4.35%-10.34%). Recipients of the Pfizer vaccine were more likely
susceptible to developing fever than recipients of the J&J vaccine (aOR=1.47, 95%CI: 1,02-2.16;
p<0.048) (Table 3).

194

Independent	Group	Fever(-)	Fever	% Fever	aOR (95%CI)	P-value
Variables			(+)			
Gender	Male	2,255	248	9.91%	1.07 (0.89-1.30)	0.452
	Female	2,053	210	9.28%	1 (Ref)	
Age	36 years and +	2,196	233	9.59%	0.96(0.82-1.20)	0.963
	<36 years	2,112	225	9.63%	1 (Ref)	
Type of Vaccine	Pfizer	224	32	12.5%	1.47(1,002-2.16)	0.048*
	Johnson &	4,084	426	9.45%	1 (Ref)	
	Johnson					

196 Table 3: Factors Associated with Fever

197 * Significant factors, p<0.05

The proportion of persistent pain at the injection site was higher for Pfizer vaccine recipients 198 (15. 23%, 95%CI: 11.06%-20.23%%) vs J&J vaccine recipients (8.65%, 95%CI: 4.29%-9.51%). 199 200 Respondents vaccinated with the Pfizer Vaccine had a 76% increased risk of reporting pain at the 201 injection site than those vaccinated with the J&J vaccine (aOR=1.76,95%CI: 1.21-5.56; p<0.003). 202 Respondents aged 36 years and older also had a 36% increased risk of reporting pain at the site 203 of injection compared to those aged below 36 years (aOR=1.36, 95%CI: 1.11-1.66; p<0.003). Although not statistically significant, the incidence of persistent pain at the injection site was 204 205 higher after the 2nd dose (18.52%, 95%CI 6.30%-38.08%) than the first dose (8.95%, 95%CI: 8.15-206 %-9.79%) (Table 4)

208 Table 4: Factors associated with persistent pain at the injection site

Independent Variables	Groups	Pain (-)	Pain	% Injection	aOR (95%CI)	P-Value
			(+)	site pain		
	Male	2,280	223	8.91%	0.97(0.79-1.18)	0.756
Gender	Female	2,057	206	9.10%	1 (Ref)	
Age group	36 Years and +	2,181	248	10.21%	1.36(1.11-1.66)	0.003*
	<36 years	2,156	181	7.74%	1 (Ref)	
	Pfizer	217	39	15.23%	1.76(1.21-5.56)	0.003*
Type of Vaccine	Johnson & Johnson	4,120	390	8.65%	1 (Ref)	
Number of doses	1 st dose	4,315	424	8.95%	0.75(0.27-2.12)	0.598
administered	2 nd dose	22	5	18.52%	1 (Ref)	

209

* Significant factors, p<0.05

210 Headache was more reported among Pfizer vaccine recipients (9.77%, 95%CI: 6.42%-14.07) than J&J vaccine recipients (3.79%, 95%CI: 3.25%-4.39%), muscle pain was reported by 3.52% (95%CI: 211 212 1.62%-6.57%) of Pfizer vaccine recipients vs 1.02% (95%CI; 0.75%-1.35) of J&J vaccine recipients. The more significant proportion of Pfizer vaccine recipients reported two or more symptoms 213 (10.94%, 95%CI: 7.39%-15.41%) than J&J vaccine recipients (4.06%, 95%CI: 3.50%-4.65%). 214 215 Respondents aged 36 years and more had a 46% increased risk of complaining of 2 side effects 216 or more compared to those aged below 36 years (aOR=1.46, 95%CI: 1.10-1.94; p<0.008).

- 217 While all AEs were more predominant in Pfizer than in J&J vaccine, the odds were particularly
- 218 higher for headache (aOR=2.8, 95%CI: 1.80-4.42; p<0.001) (Table 5), myalgia (aOR=3.79, 95%CI:
- 219 1.83-7.84; p<0.001) (Table 6) and reporting two signs or more (aOR=3.02, 95%CI: 1.97-4.63;
- 220 p<0.001). (Table 7)

221 Table 5: Factors associated with headache

Independent	Groups	Headach	Headac	%	OR (95%CI)	P-Value
Variables		e (-)	he (+)	Headache		
Gender	Male	2,398	105	4.19%	1.05 (0.79-1,40)	0.707
	Female	2,172	91	4.02%	1 (Ref)	
	36 Years and +	2,329	100	4.12%	1.00 (0.75-1.34)	0.970
Age	<36 years	2,241	96	4.11%	1 (Ref)	
	Pfizer	231	25	9.77%	2.82 (1.80-4.42)	0.001*
Type of Vaccine	Johnson & Johnson	4,339	171	3.79%	1 (Ref)	
Number of	1 st dose	4,544	190	4.11%	2.85(0.37-21.93)	0.313
doses administered	2 nd dose	21	6	3.70%	1 (Ref)	

222 * Significant factors, p<0.05

223

224

226 Table 6: Factors associated with muscle pain

Independent						P-
Variables	Groups	Myalgia (-)	Myalgia (+)	% Myalgia	aOR(95%CI)	Value
	Male	2,474	29	1.16%	1.01(0.59-1.73)	0.96
Gender	Female	2,237	26	1.15%	1 (Ref)	
Age	36 years and +	2,398	31	1.28%	1.25(0.74-2.15)	0.401
	<36 years	2,313	24	1.03%	1 (Ref)	
Type of Vaccine	Pfizer	247	9	3.52%	3.79(1.83-7.84)	0.001*
	1& 1	4,464	46	1.02%	1 (Ref)	
Number of doses	1 st dose	4,684	55	1.16%	Omitted	
administered	2 nd dose	27	0	0.00%		

227 * Significant factors, p<0.05

228 **Table 7: Factors associated with the number of signs reported by an individual**

Independent	Groups	< 2	2 signs	% 2 signs	aOR(95%CI)	P-value
Variables		signs	and +	and +		
	Female	2,163	100	4.43%	0.99 (0.76-1.32)	0.992
Gender	Male	2,392	111	4.42%	1 (Ref)	
Age	36 Years and +	2,303	126	5.19%	1.46 (1.10-1.94)	0.008*
	<36 years	2,252	85	3.64%	1 (Ref)	

Pfizer	228	28	10.94%	3.02 (1.97-4.63)	0.001*
Johnson & Johnson	4,327	183	4.06%	1 (Ref)	
1 st dose	4,529	211	4.43%	3.37 (0.44-25.83)	0.242
2 nd dose	26	1	3.57%	1 (Ref)	
	Johnson & Johnson 1 st dose	Johnson & Johnson 4,327 1 st dose 4,529	Johnson & Johnson 4,327 183 1 st dose 4,529 211	Johnson & Johnson 4,327 183 4.06% 1 st dose 4,529 211 4.43%	Johnson & Johnson 4,327 183 4.06% 1 (Ref) 1 st dose 4,529 211 4.43% 3.37 (0.44-25.83)

229 * Significant factors, p<0.05

230 **Discussion**

231 The clinical trials during the development of COVID-19 vaccines were mainly conducted in developed nations, so they might not optimally represent the safety situation in the African 232 setting. The findings from our safety surveillance analysis indicate that a significant proportion of 233 COVID-19 vaccine recipients experienced AEFIs. Specifically, the study revealed that about a 234 guarter of individuals who received the vaccine reported any AEFIs and the AEFIs were related to 235 the type of vaccines administered and the age of the recipients. This finding is consistent with 236 clinical trials. In the results from the clinical trial on the safety of mRNA vaccines, more mRNA 237 238 recipients than placebo recipients reported any adverse event (27% and 12%, respectively) or a related adverse event (21% and 5%).¹¹ There was a slight difference between the first and second 239 240 dose, with 23.76% (95%CI: 22.55%-24.99%) experiencing AEFIs after receiving the first dose and 241 22.22% (95%CI: 8.62%-42.26%) after the second. Furthermore, it was observed that a higher proportion of individuals who received the Pfizer vaccine (34.38%, 95% CI: 28.57%%-40.54%) 242 reported AEFIs compared to those who received the J&J vaccine (23.15%, 95% CI: 21.92%-243 24.41%). 244

Considerable differences were observed in the trends of AEFIs compared with results from the 245 246 participant-reporting studies. The UK app study showed that 71.9% (dose 1) and 68.2% (dose 2) reported local side effects. ¹² In the US online cohort study, AEs were reported to be 64.9% 247 partially vaccinated and 80.3% fully vaccinated with the mRNA vaccine.¹³ The proportion of AEs 248 249 was generally lower in our study. We can speculate that the difference might be due to potential age differences in the study cohort. In our study, the population mainly comprised of younger 250 individuals (median age of 36 years) compared with the studies mentioned above (54 years; UK 251 252 study; 59–64 years; US study), contrasting trends of AEFIs and association of age was observed, 253 unlike other studies. Moreover, we did not assess whether participants were pre-medicated before vaccination. A study conducted in Ghana revealed that almost half of the respondents 254 pre-medicated with paracetamol before vaccination.¹⁴ The importance of this factor cannot be 255 ruled out since it may contribute significantly to how an individual's immune system responds to 256 257 the vaccine. This creates an avenue for further research to determine if this is the case. Another explanation might be that for participant-reporting studies, the vaccinees without AEs might be 258 less motivated to proactively report Zero AEFI, leading to more reports from those who 259 experienced AEs. 260

261 Forms of AEFI

Findings from this study showed that the most common adverse event experienced among the majority after COVID-19 vaccination included fever (458 cases), pain on injection site (429 cases), headache (196 cases), stiffness (72 cases), and myalgia (55 cases). The adverse events experienced were no different from those experienced across the world.¹⁵ In the Ethiopian study

conducted by Jerso et al. on healthcare workers vaccinated against COVID-19¹⁶, the most 266 267 prevalent symptoms experienced in descending order include - pain at the injection site (64.1%), fatigue (35.7%), headache (28.9%), joint pain (26.5%) and muscle pain (21.5%). In the study 268 269 conducted in Ghana, the prevalence of pain at the injection site also hovered around a similar 270 figure of 65.8%, which was also the most common symptom experienced post-COVID-19 vaccination. The second most common symptom was headache (57.5%), followed by the 271 272 following—tiredness (55.8%), fever (51.7%), chills (39.6%), and muscle pains (38.3%).¹⁴ In our 273 study, pain at the injection site was the second most common symptom after fever. It is, 274 however, difficult to compare those studies to ours because J&J and Pfizer were not the predominant vaccines administered in those studies. However, the running theme seems to be 275 276 that pain at the injection site was among the first 2 most common adverse events or side effects in all studies mentioned. 277

Although not statistically significant, the occurrence of injection site pain in our study was higher among vaccine recipients of the second dose than those with the first dose (18.5% vs 8.9%). These results corroborate the findings of the clinical trials that revealed that the proportion of almost all AEFIs was higher in recipients of the second dose.¹⁷¹⁸ Similar to previous studies, injection site pain and muscle pain were among the most predominant AEs.^{19,20}

283

284

286 Seriousness of AEFIs

In our findings, 6 (0.13%) serious AEs were reported. In the clinical trial on the safety of mRNA
 vaccines, the incidence of serious adverse events was similar in the vaccine and placebo groups
 (0.6% and 0.5%, respectively).¹⁷

290 Factors Associated with AEFIs

Our findings revealed that the vaccine type was the most significant factor that may impact AEs. 291 Pfizer vaccine recipients were significantly associated with greater odds of reporting fever 292 (aOR=1.47, 95%CI: 1,02-2.16; p<0.048), headache (aOR=2.8, 95%CI: 1.80-4.42; p<0.001), 293 injection site pain (aOR=1.76,95%CI:1.21-5.56; p<0.003)), and having more than 2 signs 294 (aOR=3.02, 95%CI: 1.97-4.63; p<0.001), compared to the J&J vaccine recipients. Particularly, 295 Pfizer (an mRNA vaccine) was significantly associated with higher odds of AEs than J&J. These 296 results were consistent with the findings of clinical trials^{17,18} survey-based studies^{13,21,22} and a 297 government-sponsored surveillance study²³. 298

Of the baseline characteristics, female gender was not one of the evident factors associated with AEFIs in this study. This was considerably different from previous findings, which showed that the overall incidence of AEs in women was generally higher than that in men.^{13,21} A notable finding from these studies was that female participants reported menstrual disorders and unexpected vaginal bleeding after mRNA vaccination. Menstrual disorders and unexpected vaginal bleeding should be carefully monitored in future surveys.

306 Limitations

Our results should be interpreted with caution given the following limitations. First, there might 307 be potential misclassification of outcomes, as AEFIs reported by the participants were not 308 309 medically reviewed and classification of the AEFI has not been conducted. Secondly, our survey 310 focused only on specific AEFIs using a pre-identified list, limiting the scope and potentially excluding other AEFIs. Thirdly, as we only examined the short-term safety of COVID-19 vaccines, 311 further studies are required to evaluate the long-term AEs. Lastly, this survey did not assess for 312 any pre-existing medical conditions or whether participants were pre-medicated before 313 vaccination. 314

315 **Conclusion**

In conclusion, this survey conducted in Kinshasa (DRC) revealed that approximately 24% of 316 COVID-19 vaccine recipients aged 5–90 years reported AEFIs, and most of AEFIs were mild and 317 transient. Fever, Injection site pain, headache, and muscle pain were the most predominant AEFIs 318 319 reported by COVID-19 vaccine recipients. We also found that vaccination with the Pfizer vaccine 320 and age of 36 years or more were associated with the incidence of AEFIs. The Pfizer vaccine was 321 significantly associated with greater odds of reporting fever, headache, muscle pain, injection site pain, and more than 2 signs compared to the J&J vaccine. Individuals aged 36 years or more 322 323 were associated with greater odds of reporting pain at injection site and having more than 2 AEFIs. Further safety surveys monitoring all potential factors are needed to generate more 324 325 evidence on COVID-19 vaccine safety in an African population. This information will support 326 establishing future vaccination strategies tailored to individuals potentially susceptible to AEFIs.

327 Acknowledgments

- 328 We thank the participants in this study for their great contribution to safety surveillance and the
- 329 Ministry of Health for sharing data with Africa CDC to enable this analysis.

330 **References**

- WHO. Protocol template to be used as template for observational study protocols: cohort
 event monitoring (CEM) for safety signal detection after vaccination with COVID-19
 vaccines [Internet]. 2021 [cited 2024 Jan 8]. Available from:
- 334 https://www.who.int/publications/i/item/9789240027398
- Islam A, Bashir MS, Joyce K, Rashid H, Laher I, Elshazly S. An Update on COVID-19 Vaccine
 Induced Thrombotic Thrombocytopenia Syndrome and Some Management
 Recommendations. Molecules [Internet]. 2021 Aug 2 [cited 2024 Jan 8];26(16). Available
- 338 from: /pmc/articles/PMC8400504/
- 339 3. Centers for Disease Control and Prevention. Myocarditis and Pericarditis After mRNA
- 340 COVID-19 Vaccination | CDC [Internet]. Centers for Disease Control and Prevention. 2021
- 341 [cited 2024 Jan 8]. Available from: https://www.cdc.gov/coronavirus/2019-
- 342 ncov/vaccines/safety/myocarditis.html
- 343 4. World Health Organization. Vaccine Safety Basics | OpenWHO [Internet]. [cited 2024 Jan
- 344 8]. Available from: https://openwho.org/courses/vaccine-safety-basics
- World Health Organization. Safety Surveillance Manual Safety Surveillance. Available
 from: Safety Surveillance Manual Safety Surveillance.

347 6. WHO. Safety Monitoring of Medicinal Products: Reporting Systems For The General Public.

- 348
 2000
 [cited
 2024
 Jan
 8];35(3):41–3.
 Available
 from:

 349
 http://www.scopus.com/inward/record.url?eid=2-s2.0
- 350 0025317538&partnerID=40&md5=6ff30e08e26b99f08c46a3bb4c28a332
- Our World in Data. Total number of people who received at least one dose of COVID-19
 vaccine [Internet]. Our World in Data. 2023 [cited 2024 Jan 8]. Available from:
 https://ourworldindata.org/grapher/people-vaccinated-covid
- Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. A Single
 Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and
 Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity [Internet]. 2020 Oct
 [cited 2024 Jan 8];53(4):724. Available from: /pmc/articles/PMC7392193/
- Vanaparthy R, Mohan G, Vasireddy D, Atluri P. Review of COVID-19 viral vector-based
 vaccines and COVID-19 variants. Le Infez Med [Internet]. 2021 [cited 2024 Jan
- 360 8];29(3):328–38. Available from: https://pubmed.ncbi.nlm.nih.gov/35146337/
- 36110.Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported362From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem [Internet]. 2021
- 363 Oct 1 [cited 2024 Jan 8];36(4):427. Available from: /pmc/articles/PMC7997788/
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy
 of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet]. 2020 Dec 31 [cited 2024
 Jan 8];383(27):2603–15. Available from: https://pubmed.ncbi.nlm.nih.gov/33301246/

367	12.	Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects ar
368		SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in th
369		UK: a prospective observational study. Lancet Infect Dis [Internet]. 2021 Jul 1 [cited 202
370		Jan 8];21(7):939–49. Available from: https://pubmed.ncbi.nlm.nih.gov/33930320/
371	13.	Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-1
372		Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw open [Internet]. 202
373		Dec 22 [cited 2024 Jan 9];4(12). Available from
374		https://pubmed.ncbi.nlm.nih.gov/34935921/
375	14.	Boi-Dsane NAA, Dzudzor B, Alhassan Y, Aheto JMK. Prevalence of common adverse even
376		experienced following COVID-19 vaccination and its associated factors in Ghana: Cros
377		sectional study design. Heal Sci reports [Internet]. 2022 Jan 1 [cited 2024 Jan 9];6(1
378		Available from: https://pubmed.ncbi.nlm.nih.gov/36582625/
379	15.	Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et a
380		Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
381		Randomized Clinical Trials. Vaccines [Internet]. 2021 May 1 [cited 2024 Jan 9];9(5
382		Available from: https://pubmed.ncbi.nlm.nih.gov/34066475/
383	16.	Jarso G, Gebi W, Abdo M, Lemma M, Abebe E, Lemessa B, et al. Prevalence of COVID-1
384		Vaccine Side Effects among Early-Vaccinated Healthcare Workers in Eastern Ethiopi
385		Ethiop J Health Sci [Internet]. 2022 May 1 [cited 2024 Jan 9];32(3):473. Available from
386		/pmc/articles/PMC9214739/
387	17.	Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficad

388 of the BNT162b2 mRNA Covid-19 Vaccine. N Er	ngl J Med [Internet]. 2020 Dec 31 [cited 2024
---	---

- Jan 9];383(27):2603–15. Available from: https://pubmed.ncbi.nlm.nih.gov/33301246/
- 18. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the
- 391 mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med [Internet]. 2021 Feb 4 [cited 2024 Jan
- 392 9];384(5):403–16. Available from: https://pubmed.ncbi.nlm.nih.gov/33378609/
- 393 19. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med [Internet]. 2021 394 Sep 16 [cited 2024 9];385(12):1078-90. Available from: 395 Jan 396 https://pubmed.ncbi.nlm.nih.gov/34432976/
- 20. Chen G, Li X, Sun M, Zhou Y, Yin M, Zhao B, et al. COVID-19 mRNA Vaccines Are Generally
 Safe in the Short Term: A Vaccine Vigilance Real-World Study Says. Front Immunol. 2021
 May 21;12:669010.
- 400 21. Kitagawa H, Kaiki Y, Sugiyama A, Nagashima S, Kurisu A, Nomura T, et al. Adverse reactions
 401 to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J Infect Chemother
 402 [Internet]. 2022 Apr 1 [cited 2024 Jan 9];28(4):576–81. Available from:
 403 https://pubmed.ncbi.nlm.nih.gov/35058126/
- Valera-Rubio M, Sierra-Torres MI, Castillejo García R, Cordero-Ramos J, López-Márquez
 MR, Cruz-Salgado Ó, et al. Adverse events reported after administration of BNT162b2 and
 mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based
 study in a Spanish hospital. Expert Rev Vaccines [Internet]. 2022 [cited 2024 Jan 9];21(4):1.
- 408 Available from: /pmc/articles/PMC8787836/

- 409 23. Chapin-Bardales J, Gee J, Myers T. Reactogenicity Following Receipt of mRNA-Based
- 410 COVID-19 Vaccines. JAMA [Internet]. 2021 Jun 1 [cited 2024 Jan 9];325(21):2201–2.
- 411 Available from: https://jamanetwork.com/journals/jama/fullarticle/2778441




Figure 1: Frequency of reported AEFIs

